

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: August 11, 2011  
Electronic Signature for Li-Hsien Rin-Laures: /Li-Hsien Rin-Laures 33,547/

Docket No.: 01017/40451B  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Manfred Brockhaus et al.

Application No.: 08/444,790

Confirmation No.: 5612

Filed: May 19, 1995

Art Unit: 1646

For: HUMAN TNF RECEPTOR

Examiner: Z. C. Howard

**RESPONSE TO INTERVIEW SUMMARY**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:



This paper responds to the Examiner's Interview Summary dated July 12, 2011, and the invitation therein to supply Applicants' summary. Applicants thank Examiner Howard and the other attendees from the Patent Office for granting an interview.

Applicants agree with the Examiner's description of the matters discussed during the interview. The existing rejection, cited art, and evidence of record were discussed. The enclosed schematics (Exhibits A-E) were also shown and discussed.

Dated: August 11, 2011

Respectfully submitted,

By /Li-Hsien Rin-Laures 33,547/  
Li-Hsien Rin-Laures, M.D.  
Registration No.: 33,547  
MARSHALL, GERSTEIN & BORUN LLP  
233 S. Wacker Drive  
6300 Willis Tower  
Chicago, Illinois 60606-6357  
(312) 474-6300  
Attorney for Applicant




62. (Previously presented) A protein comprising  
 (a) a human tumor necrosis factor (TNF)-binding soluble fragment of  
 an insoluble human TNF receptor, wherein the insoluble human TNF receptor (i)  
 specifically binds human TNF, (ii) has an apparent molecular weight of about 75  
 kilodaltons on a non-reducing SDS-polyacrylamide gel, and (iii) comprises the  
 amino acid sequence LPAQVAFXPYAPEPGSTC (SEQ ID NO: 10); and  
 (b) all of the domains of the constant region of a human  
 immunoglobulin IgG heavy chain other than the first domain of said constant  
 region;

**Embodiment of the claimed invention**

wherein said protein specifically binds human TNF.

**EXHIBIT A**


## Dembic and Capon



Embodiment of the claimed invention


**EXHIBIT B**

**Smith et al. (U.S. Patent. 5,395,760)**





"A recombinant chimeric antibody molecule may also be produced having TNF-R sequences substituted for the variable domains of either or both of the immunoglobulin molecule heavy and light chains and having unmodified constant region domains." (Smith patent, col. 10, lines 53-68)

**EXHIBIT C**




Suggested Chimeric Antibody Molecules in Smith



The Claimed Molecules

**EXHIBIT D**

# Schematic: Proteins Tested in Arora Declaration



**EXHIBIT E**